Clinical characterization of hemophagocytic lymphohistiocytosis caused by immune checkpoint inhibitors: a review of published cases

References

• Qingyi S, Yonghong X. Research progress on etiology and pathogenesis of hemophagocytic lymphohistiocytosis. Zhejiang Medical College. 2018;40(02):210–213.
   Google Scholar
• Schweisberger C, Palaniappan N, Wood NM, et al. Management and outcomes in secondary diabetes among pediatric patients hospitalized with hemophagocytic lymphohistiocytosis. J Pediatr Endocrinol Metab. 2023;36(7):692–696. doi:10.1515/jpem-2023-0206
   PubMed Web of Science ®Google Scholar
• Jia A, Yongdong S. Etiology, diagnosis and treatment of hemophagocytic lymphohistiocytosis. Laboratory Medicine and Clinic. 2018;15(22):3475–3477.
   Google Scholar
• Shuangshuang L, Jian Y. Research progress of hemophagocytic lymphohistiocytosis. South China Journal of National Defense Medicine. 2019;33(02):138–141.
   Google Scholar
• Henter JI, Horne A, Aricó M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124–131. doi:10.1002/pbc.21039. PMID: 16937360.
   PubMed Web of Science ®Google Scholar
• Griffin G, Shenoi S, Hughes GC. Hemophagocytic lymphohistiocytosis: An update on pathogenesis, diagnosis, and therapy. Best Pract Res Clin Rheumatol. 2020;34(4):101515. doi:10.1016/j.berh.2020.101515. Epub 2020 May 7. PMID: 32387063.
   PubMed Web of Science ®Google Scholar
• Fardet L, Galicier L, Lambotte O, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66(9):2613–2620. doi:10.1002/art.38690. PMID: 24782338.
   PubMed Web of Science ®Google Scholar
• Li X, Shao C, Shi Y, et al. Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. J Hematol Oncol. 2018;11:31), doi:10.1186/s13045-018-0578-4
   PubMed Web of Science ®Google Scholar
• Li Y, Li F, Jiang F, et al. A mini-review for cancer immunotherapy: molecular understanding of PD-1/PD-L1 pathway & translational blockade of immune checkpoints. Int J Mol Sci. 2016;17(7):1151. doi:10.3390/ijms17071151
   PubMed Web of Science ®Google Scholar
• Poto R, Troiani T, Criscuolo G, et al. Holistic approach to immune checkpoint inhibitor-related adverse events. Front Immunol. 2022;13:804597. doi:10.3389/fimmu.2022.804597
   PubMedGoogle Scholar
• Diaz L, Jauzelon B, Dillies AC, et al. Hemophagocytic lymphohistiocytosis associated with immunological checkpoint inhibitors: A pharmacovigilance study. J Clin Med. 2023;12(5):1985. doi:10.3390/jcm12051985
   PubMed Web of Science ®Google Scholar
• Noseda R, Bertoli R, Müller L, et al. Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports. J Immunother Cancer. 2019;7(1):117. doi:10.1186/s40425-019-0598-9
   PubMed Web of Science ®Google Scholar
• Pacholczak-Madej R, Grela-Wojewoda A, Lompart J, et al. Effective treatment of a melanoma patient with hemophagocytic lymphohistiocytosis after nivolumab and ipilimumab combined immunotherapy. Prague Med Rep. 2022;123(1):35–42. PMID: 35248163. doi:10.14712/23362936.2022.4
   PubMedGoogle Scholar
• Mizuta H, Nakano E, Takahashi A, et al. Hemophagocytic lymphohistiocytosis with advanced malignant melanoma accompanied by ipilimumab and nivolumab: A case report and literature review. Dermatol Ther. 2020;33(3):e13321. doi:10.1111/dth.13321. Epub 2020 Mar 25. PMID: 32191382.
   PubMed Web of Science ®Google Scholar
• Masood A, Wahab A, Clifford T, et al. Secondary hemophagocytic lymphohistiocytosis due to nivolumab/ipilimumab in a renal cell cancer patient—a case report. Clin Case Rep. 2021;9(12):e05184. doi:10.1002/ccr3.5184
   PubMed Web of Science ®Google Scholar
• Hagiwara S, Tanizaki J, Hayashi H, et al. Hemophagocytic lymphohistiocytosis induced by nivolumab/ipilimumab combination therapy: a case of lung adenocarcinoma that responded to early steroid pulse therapy. Cancer Rep (Hoboken). 2024;7(2):e1960. doi:10.1002/cnr2.1960. Epub 2024 Jan 9. PMID: 38196303; PMCID: PMC10849979.
   PubMedGoogle Scholar
• Sadaat M, Jang S. Hemophagocytic lymphohistiocytosis with immunotherapy: brief review and case report. J Immunother Cancer. 2018;6(1):49. doi:10.1186/s40425-018-0365-3. PMID: 29871698; PMCID: PMC5989389
   PubMed Web of Science ®Google Scholar
• Hantel A, Gabster B, Cheng JX, et al. Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab. J Immunother Cancer. 2018;6(1):73. doi:10.1186/s40425-018-0384-0. PMID: 30012206; PMCID: PMC6048909.
   PubMedGoogle Scholar
• Mosalem O, Pai T, Alqawasma M, et al. Severe cytokine release syndrome and hemophagocytic lymphohistiocytosis (HLH)-like syndrome following administration of combined brentuximab vedotin and nivolumab for recurrent classical hodgkin lymphoma: a case report. J Blood Med. 2024;15:29–34. doi:10.2147/JBM.S444004
   PubMed Web of Science ®Google Scholar
• Azari AE, Stratton R, Singh A. First case of hemophagocytic lymphohistiocytosis secondary to cabozantinib with checkpoint inhibitors. Rheumatology (Oxford). 2021;60(5):e167–e168. doi:10.1093/rheumatology/keaa750. PMID: 33280022.
   PubMed Web of Science ®Google Scholar
• Honjo O, Kubo T, Sugaya F, et al. Severe cytokine release syndrome resulting in purpura fulminans despite successful response to nivolumab therapy in a patient with pleomorphic carcinoma of the lung: a case report. J Immunother Cancer. 2019;7(1):97. PMID: 30944043; PMCID: PMC6448268. doi:10.1186/s40425-019-0582-4
   PubMedGoogle Scholar
• Okawa S, Kayatani H, Fujiwara K, et al. Pembrolizumab-induced autoimmune hemolytic anemia and hemophagocytic lymphohistiocytosis in non-small cell lung cancer. Intern Med. 2019;58(5):699–702. doi:10.2169/internalmedicine.1001-18. Epub 2019 Mar 1. PMID: 30828042; PMCID: PMC6443545.
   PubMed Web of Science ®Google Scholar
• Akagi Y, Awano N, Inomata M, et al. Hemophagocytic lymphohistiocytosis in a patient with rheumatoid arthritis on pembrolizumab for lung adenocarcinoma. Intern Med. 2020;59(8):1075–1080. Epub 2020 Feb 1. PMID: 32009093; PMCID: PMC7205536. doi:10.2169/internalmedicine.3889-19
   PubMed Web of Science ®Google Scholar
• Lorenz G, Schul L, Bachmann Q, et al. Hemophagocytic lymphohistiocytosis secondary to pembrolizumab treatment with insufficient response to high-dose steroids. Rheumatology (Oxford). 2019;58(6):1106–1109. doi:10.1093/rheumatology/key447. PMID: 30668880.
   PubMed Web of Science ®Google Scholar
• Zhai C, Jin X, You L, et al. Hemophagocytic lymphohistiocytosis following pembrolizumab and bevacizumab combination therapy for cervical cancer: a case report and systematic review. BMC Geriatr. 2024;24(1):32. doi:10.1186/s12877-023-04625-3. PMID: 38191289; PMCID: PMC10773023
   PubMed Web of Science ®Google Scholar
• Al-Samkari H, Snyder GD, Nikiforow S, et al. Haemophagocytic lymphohistiocytosis complicating pembrolizumab treatment for metastatic breast cancer in a patient with the PRF1A91V gene polymorphism. J Med Genet. 2019;56(1):39–42. doi:10.1136/jmedgenet-2018-105485. Epub 2018 Oct 4. PMID: 30287596.
   PubMed Web of Science ®Google Scholar
• Rubio-Perez J, Rodríguez-Perez ÁR, Díaz-Blázquez M, et al. Treatment-related hemophagocytic lymphohistiocytosis due to atezolizumab: a case report and review of the literature. J Med Case Rep. 2022;16(1):365), doi:10.1186/s13256-022-03585-3. PMID: 36195892; PMCID: PMC9531226.
   PubMedGoogle Scholar
• Shah D, Shrestha R, Ramlal R, et al. Pembrolizumab associated hemophagocytic lymphohistiocytosis. Ann Oncol. 2017;28(6):1403. doi:10.1093/annonc/mdx113. PMID: 28368439.
   PubMed Web of Science ®Google Scholar
• Dirven I, Vander Mijnsbrugge AS, Mignon S, et al. Auto-immune hemolytic anemia and hemophagocytic lymphohistiocytosis as immune-related adverse event in patients with metastatic melanoma and concurrent chronic lymphocytic leukemia: a case series and literature review. Melanoma Res. 2023;33(4):338–344. doi:10.1097/CMR.0000000000000895. Epub 2023 Apr 28. PMID: 37114670
   PubMed Web of Science ®Google Scholar
• Satzger I, Ivanyi P, Länger F, et al. Treatment-related hemophagocytic lymphohistiocytosis secondary to checkpoint inhibition with nivolumab plus ipilimumab. Eur J Cancer. 2018;93(4):150–153. doi:10.1016/j.ejca.2018.01.063. Epub 2018 Feb 19. PMID: 29472154.
   PubMedGoogle Scholar
• Costa CM, Gadotti LL, Seiwald MC, et al. Ganglionar tuberculosis infection evolving to hemophagocytic lymphohistiocytosis after anti-programmed cell death 1 treatment for high-risk melanoma: a case report. J Med Case Rep. 2021;15(1):350. doi:10.1186/s13256-021-02900-8
   PubMedGoogle Scholar
• Ghous G, Shoukat HMH, Tarar ZI, et al. Encephalitis associated With hemophagocytic lymphohistiocytosis secondary to immune checkpoint inhibitors: An unfamiliar spin-off. Cureus. 2021;13(6):e16079. doi:10.7759/cureus.16079. PMID: 34345559; PMCID: PMC8324828.
   PubMedGoogle Scholar
• Takeshita M, Anai S, Mishima S, et al. Coincidence of immunotherapy-associated hemophagocytic syndrome and rapid tumor regression. Ann Oncol. 2017;28(1):186–189. doi:10.1093/annonc/mdw537. PMID: 28043982.
   PubMed Web of Science ®Google Scholar
• Choi S, Zhou M, Bahrani E, et al. Rare and fatal complication of immune checkpoint inhibition: a case report of haemophagocytic lymphohistiocytosis with severe lichenoid dermatitis. Br J Haematol. 2021;193(6):e44–e47. doi:10.1111/bjh.17442. Epub 2021 May 5. PMID: 33954981.
   PubMed Web of Science ®Google Scholar
• Özdemir BC, Latifyan S, Perreau M, et al. Cytokine-directed therapy with tocilizumab for immune checkpoint inhibitor-related hemophagocytic lymphohistiocytosis. Ann Oncol. 2020;31(12):1775–1778. doi:10.1016/j.annonc.2020.08.2101. Epub 2020 Aug 25. PMID: 32858151.
   PubMed Web of Science ®Google Scholar
• Kurozumi A, Takahashi H, Watanabe T, et al. Two cases of lung cancer with hemophagocytic lymphohistiocytosis caused by immune checkpoint inhibitors. Thorac Cancer. 2021;12(10):1625–1628. doi:10.1111/1759-7714.13954. Epub 2021 Mar 30. PMID: 33783978; PMCID: PMC8107030
   PubMed Web of Science ®Google Scholar
• Dupré A, Michot JM, Schoeffler A, et al. Haemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitors: a descriptive case study and literature review. Br J Haematol. 2020;189(5):985–992. doi:10.1111/bjh.16630. Epub 2020 Apr 3. PMID: 32243578.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. doi:10.3322/caac.21708
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Brito-Zerón P, López-Guillermo A, et al. Adult haemophagocytic syndrome. Lancet. 2014;383(9927):1503–1516. Epub 2013 Nov 27. Erratum in: Lancet. 2014 Apr 26;383(9927):1464. PMID: 24290661. doi:10.1016/S0140-6736(13)61048-X
   PubMed Web of Science ®Google Scholar
• Fardet L, Galicier L, Lambotte O, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66(9):2613–2620. doi:10.1002/art.38690. PMID: 24782338.
   PubMed Web of Science ®Google Scholar
• Zoref-Lorenz A, Murakami J, Hofstetter L, et al. An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosis. Blood. 2022;139(7):1098–1110. doi:10.1182/blood.2021012764. PMID: 34780598; PMCID: PMC8854682.
   PubMed Web of Science ®Google Scholar
• Abdou Y, Pandey M, Sarma M, et al. Mechanism-based treatment of cancer with immune checkpoint inhibitor therapies. Br J Clin Pharmacol. 2020;86(9):1690–1702. doi:10.1111/bcp.14316. Epub 2020 May 12. PMID: 32323342; PMCID: PMC8176998.
   PubMed Web of Science ®Google Scholar
• Gordon SR, Maute RL, Dulken BW, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017;545(7655):495–499. doi:10.1038/nature22396
   PubMed Web of Science ®Google Scholar
• Zappasodi R, Serganova I, Cohen IJ, et al. CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours. Nature. 2021;591(7851):652–658.
   PubMed Web of Science ®Google Scholar
• Yang J, Yan J, Liu B. Targeting VEGF/VEGFR to modulate antitumor immunity. Front Immunol. 2018;9:978. doi:10.3389/fimmu.2018.00978
   PubMed Web of Science ®Google Scholar
• Gu T, Jiang A, Zhou C, et al. Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysis. Int J Cancer. 2023;152(3):480–495. doi:10.1002/ijc.34332. Epub 2022 Nov 3. PMID: 36274626.
   PubMed Web of Science ®Google Scholar
• Bai S, Tian T, Pacheco JM, et al. Immune-related adverse event profile of combination treatment of PD-(L)1 checkpoint inhibitors and bevacizumab in non-small cell lung cancer patients: data from the FDA adverse event reporting system. Transl Lung Cancer Res. 2021;10(6):2614–2624. PMID: 34295666; PMCID: PMC8264309. doi:10.21037/tlcr-21-464
   PubMed Web of Science ®Google Scholar
• Les I, Martínez M, Narro A, et al. Association of immune-related adverse events induced by nivolumab with a battery of autoantibodies. Ann Med. 2021;53(1):762–769. doi:10.1080/07853890.2021.1931956. PMID: 34060971; PMCID: PMC8172225.
   PubMed Web of Science ®Google Scholar
• Toi Y, Sugawara S, Sugisaka J, et al. Profiling preexisting antibodies in patients treated With anti-PD-1 therapy for advanced non-small cell lung cancer. JAMA Oncol. 2019;5(3):376–383. doi:10.1001/jamaoncol.2018.5860. PMID: 30589930; PMCID: PMC6439838.
   PubMed Web of Science ®Google Scholar
• Al-Samkari H, Snyder GD, Nikiforow S, et al. Haemophagocytic lymphohistiocytosis complicating pembrolizumab treatment for metastatic breast cancer in a patient with the PRF1A91V gene polymorphism. J Med Genet. 2019;56(1):39–42. doi:10.1136/jmedgenet-2018-105485. Epub 2018 Oct 4. PMID: 30287596.
   PubMed Web of Science ®Google Scholar
• Liu P, Pan X, Chen C, et al. Nivolumab treatment of relapsed/refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults. Blood. 2020;135(11):826–833. doi:10.1182/blood.2019003886. PMID: 31914172.
   PubMed Web of Science ®Google Scholar
• Zhu M, Zhang J, Shi Q, et al. Rescue of HLH with T and B lymphocyte involvement due to Epstein-Barr virus by PD-1 inhibitor/ruxolitinib and rituximab combination regimens: A case report. Iran J Immunol. 2023;20(4):466–472. doi:10.22034/iji.2023.99254.2629. Epub 2023 Oct 24. PMID: 37873944.
   PubMed Web of Science ®Google Scholar
• Tay SH, Toh MMX, Thian YL, et al. Cytokine release syndrome in cancer patients receiving immune checkpoint inhibitors: a case series of 25 patients and review of the literature. Front Immunol. 2022;13:807050. doi:10.3389/fimmu.2022.807050
   PubMedGoogle Scholar
• Shimabukuro-Vornhagen A, Gödel P, Subklewe M, et al. Cytokine release syndrome. J Immunother Cancer. 2018;6(1):56. doi:10.1186/s40425-018-0343-9
   PubMed Web of Science ®Google Scholar
• Hines M, Bhatt N, Talano JAM. Critical care of the pediatric immunocompromised hematology/oncology patient. Criti Care Pediat Immunocomp Hematol. 2019: 159–182. doi:10.1007/978-3-030-01322-6_9
   Google Scholar
• Santomasso BD, Nastoupil LJ, Adkins S, et al. Management of immune-related adverse events in patients treated With chimeric antigen receptor T-cell therapy: ASCO guideline. J Clin Oncol. 2021;39(35):3978–3992. doi:10.1200/JCO.21.01992. Epub 2021 Nov 1. Erratum in: J Clin Oncol. 2022 Mar 10;40(8):919. PMID: 34724386.
   PubMed Web of Science ®Google Scholar
• Shakoory B, Geerlinks A, Wilejto M, et al. & HLH/MAS Task Force. The 2022 EULAR/ACR Points to Consider at the Early Stages of Diagnosis and Management of Suspected Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS). Ann Rheum Dis. 2023;82(10):1271–1285. Epub 2023 Jul 24. PMID: 37487610
   PubMed Web of Science ®Google Scholar
• Takeshita M, Anai S, Mishima S, et al. Coincidence of immunotherapy-associated hemophagocytic syndrome and rapid tumor regression. Ann Oncol. 2017;28(1):186–189. doi:10.1093/annonc/mdw537. PMID: 28043982
   PubMed Web of Science ®Google Scholar
• Fujii T, Colen RR, Bilen MA, et al. Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Invest New Drugs. 2018;36(4):638–646. Epub 2017 Nov 21. PMID: 29159766; PMCID: PMC5962379. doi:10.1007/s10637-017-0534-0
   PubMed Web of Science ®Google Scholar
• Freeman-Keller M, Kim Y, Cronin H, et al. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res. 2016;22(4):886–894. doi:10.1158/1078-0432.CCR-15-1136
   PubMed Web of Science ®Google Scholar